Therefore, in the present study our aim was to measure the levels of active MMP-9 and MMP-2, IL-17, IL-18, IL-23, and MCP-3 in the serum and CSF of MS patients and controls in order to investigate the contribution of these molecules to MS pathogenesis. This evidence concerns the gene MMP2 and myeloid sarcoma.